The Risks of Renal Angiomyolipoma: Reviewing the Evidence by Seyam, Raouf et al.
Journal of Kidney Cancer and VHL 2017; 4(4): 13–25 13
REVIEW ARTICLE
The Risks of Renal Angiomyolipoma: Reviewing the Evidence
Raouf M. Seyam, Waleed K. Alkhudair, Said A. Kattan, Mohamed F. Alotaibi, Hassan M. Alzahrani, 
Waleed M. Altaweel
Department of Urology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi  Arabia
Abstract
Renal angiomyolipoma (RAML), though a rare benign tumor, may impose a significant morbidity or even mortality due to 
its unique characteristics and the complications subsequent to its treatment. The classic tumor variant is composed of smooth 
muscular, vascular, and fatty components. The most straightforward diagnosis is when the fat component is abundant and gives a 
characteristic appearance on different imaging studies. In fat-poor lesions, however, the diagnosis is difficult and presumed a renal 
cell carcinoma. Yet, some variants of RAML, though rare, express an aggressive behavior leading to metastasis and mortality. 
The challenge lies in the early detection of benign variants and identifying aggressive lesions for proper management. Another 
challenge is when the vascular tissue component predominates and poses a risk of hemorrhage that may extend to the retroperi-
toneum in a massive life-threatening condition. The predicament here is to identify the characteristics of tumors at risk of bleed-
ing and provide a prophylactic treatment. According to the clinical presentation, different treatment modalities, prophylactic or 
therapeutic, are available that span the spectrum of observation, embolization, or surgery. Renal impairment may result from 
extensive tumor burden or as a complication of the management itself. Improvement of diagnostic techniques, super-selective 
embolization, nephron-sparing surgery, and late treatment with the mammalian target of rapamycin inhibitors have provided 
more effective and safe management strategies. In this review, we examine the evidence pertaining to the risks imposed by RAML 
to the patients and identify merits and hazards associated with different treatment modalities.
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Introduction
Renal angiomyolipoma (RAML) is a rare benign tumor that 
has acquired much attention because of the risks it poses 
to patients and sometimes due to its ability to mimic renal 
cell cancer (RCC) (1–5). Sporadic RAMLs (sRAML) are 
smaller than their tuberous sclerosis (TSC)-associated coun-
terparts, usually unilateral and risk bleeding only when large. 
The indications of treatment in symptomatic patients include 
hemorrhage and pain. Asymptomatic patients are treated 
to mitigate the risk of bleeding, for the suspicion of malig-
nancy, and to prevent renal impairment. The management of 
RAML has changed over the years: while early treatment was 
nephrectomy, later a more conservative approach utilizing 
embolization and nephron sparing surgery (NSS), and finally 
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the mammalian target of rapamycin (mTOR) inhibitors has 
been proved effective to halt and reverse TSC-associated 
RAML (TSC-RAML) (2, 3). The caveats of intervention are 
mainly loss of renal tissue and function, while mTOR inhi-
bition is effective only during the time of treatment. RAML 
itself  or its treatment may cause significant morbidity and 
mortality to patients. In this article, we examine the evidence 
supporting the concerns raised by the medical community 
that justify prophylactic treatment or intervention. Mean-
while, we review the efficacy and safety of management, 
whether prophylactic or therapeutic.
Risk of Bleeding
Emergency treatment of bleeding associated with RAML 
continues to be a challenge to save the patient while preserv-
ing renal function. Several studies concluded that large le-
sions >4 cm and TSC-associated lesions are more susceptible 
to bleeding, raising the need for prophylactic management.
Acute bleeding
The most common cause of retroperitoneal bleeding of non
-traumatic renal origin, sometimes responsible for fatality, is 
RAML followed by RCC (6, 7). Retroperitoneal hemorrhage 
is associated with large lesions (1, 8), spontaneous rupture of 
RAML (9), rupture of aneurysms (10, 11), associated with 
pregnancy (12, 13), trauma even trivial (14–16) and anticoag-
ulation (17, 18). The management of bleeding RAML initially 
was nephrectomy (1, 5). A 10-year experience in the treatment 
of RAML favored nephrectomy or partial nephrectomy (PN) 
in 71.2% of patients and embolization in 28.8% (5). As tech-
nology evolved, embolization became the treatment of choice, 
leaving nephrectomy only for failed embolization in the emer-
gency setting, development of post-embolization complica-
tions, and life-threatening hemorrhage (19–21). Embolization is 
associated with a high clinical success rate more than 90% (22, 
23). Successful control of a bleeding emergency was reported in 
96–100% of patients (20, 24). Bleeding occurs in both sporadic 
and TSC-associated lesions. A pooled analysis identified 441 pa-
tients with sRAML with a mean initial lesion diameter of 6.5 cm 
(25). Major retroperitoneal bleeding occurred in 12.2% of the 
patients, and the intervention rate was high for the whole group 
including 58.1% nephrectomy or PN, 29% embolization, and 
7.3% conservative treatment. Active treatment was frequently re-
ported (67.5%) in 400 patients with RAML, whereas the remain-
ing 130 patients, 78.5% of whom were asymptomatic, underwent 
active surveillance (26). There is a consensus that symptomatic 
RAML mainly due to hemorrhage should be treated by embol-
ization and surgical excision as a second-line treatment (27, 28).
Prophylaxis against bleeding
There is controversy regarding prophylactic management of 
asymptomatic RAML. Active surveillance in patients with 
small lesions (mean size 1.7 cm) was associated with low 
growth rate (0.088 cm/year) and minimal (7%) secondary in-
tervention (29). Larger lesions may be at high risk of bleed-
ing, but there is no consensus on what size should be used 
as a cutoff  for prophylaxis (27). Although in the pediatric 
age group, the incidence of RAML in TSC patients is 50.3%, 
growth rates are unpredictable and require only radiological 
follow-up (30). In that study, while management of the renal 
lesions in 145 patients was not consistent, fortunately none of 
the patients developed retroperitoneal hemorrhage.
Several options are available for prophylaxis, ranging from 
observation up to surgery (Table 1). The most drastic prophy-
laxis is total nephrectomy for large lesions (5) (Supplementary 
Table 2; the supplementary tables of this article are available on 
the journal’s website, which can be accessed via the following 
link: http://jkcvhl.com/index.php/jkcvhl/rt/suppFiles/97/0). A 
surgeon’s preference might be driven by the less demanding pro-
cedure compared to PN. Guidelines recommend that nephrec-
tomy in TSC patients should be avoided (31). Prophylactic 
PN is contemplated by urologists as it provides a “permanent 
cure” of the resectable lesions, can be performed using mini-
mally invasive surgery either laparoscopic or robotic assisted, 
and is associated with preservation of renal function (4, 5, 29, 
32–41) (Supplementary Table 2). Surgical complications up to 
21% were reported (5, 32, 33, 35, 36, 38). Only one patient out 
of 132 in four studies developed renal failure in a follow-up of 
26 months to 8 years (32, 33, 36). No recurrence or a maximum 
recurrence rate of 3.4% developed at long-term follow-up (29, 
32, 33, 35, 36, 38). The most recent advent of NSS is robotic 
PN (RPN). Three series included prophylactic RPN reported 
mostly low-grade complications, preservation of renal func-
tion, and no recurrence of lesions (39–41). Prophylactic embo-
lization of RAML has been widely used with 85–91% success 
rate (22, 42–45) (Supplementary Table 3). The aim of prophy-
lactic treatment is to devascularize the lesion and reduce its 
size. Several studies reported a mean size reduction of 25–72% 
(46–49). No bleeding or need for surgical intervention was re-
quired in up to 17% of patients (8, 43, 44, 46, 49, 50). The caveat 
of this approach is the need of multiple retreatments (8, 22, 42, 
43, 47, 50). The highest reported complication rate was 19.5% 
(4, 8, 42, 44, 48). There is a risk of deterioration of the function 
of the treated renal unit; however, several studies showed no 
significant change in serum creatinine during a follow-up of 
23–60 months (8, 44, 49, 50). Observation and active surveil-
lance are viable options for patients who do not need active 
treatment (26, 29, 51–55) (Supplementary Table 4). Follow-up 
for 40–60 months was associated with no bleeding or size 
change (54, 55), growth in 8% (53), and need for intervention 
in 5.6–13% (26, 29, 52) or surgery in 29% (51). Observation 
for TSC-AML showed an association between severe hemor-
rhage and lesions >3.5 cm affecting 20% of patients prospec-
tively followed for 60 months (56). Others showed a lower rate 
of hemorrhage and slow growth rate at 48 months (34). The 
studies of everolimus for the treatment of TSC-AML patients 
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reported a significant reduction in lesion size and no bleeding 
at follow-up, rendering the medication an important prophy-
lactic option (2, 57) (Supplementary Table 5).
For asymptomatic patients, the European Association of 
Urology guidelines recommend surveillance and for high-risk 
patients embolization, PN, nephrectomy, or everolimus, al-
beit, with a weak evidence supporting any of these choices 
(27). High risk includes large lesion (size disputed), women in 
childbearing age and inadequate access to follow-up, or emer-
gency service. For asymptomatic patients with TSC-RAML, 
guidelines from the 2012 TSC Consensus Conference recom-
mended mTOR inhibitors as first-line short-term prophylac-
tic treatment for patients with asymptomatic lesions >3 cm 
with category 1 recommendation (28). Second-line prophy-
lactic procedures include embolization and NSS.
Several descending views challenge prophylaxis in asymp-
tomatic patients. In patients with TSC, one study reported a 
slow growth rate of RAML, with a mean inclusion mass of 
3.6 cm and a median follow-up of 4 years (34). Asymptomatic 
lesions <4 cm can be followed up conservatively and rarely 
will become complicated (53). Following patients, mostly 
asymptomatic, treated by active surveillance for a mean of 
40 months, only 13% required active treatment (26). Risk 
factors for the need of delayed intervention were tumor size 
≥4 cm and having symptoms at diagnosis. Even larger lesions 
in asymptomatic patients were successfully managed only by 
observation (54). Follow-up of 22 renal units in asymptom-
atic patients, with four lesions 4–10 cm in diameter, showed 
no bleeding and only one progression in size at a mean dura-
tion of 3.8 years.
Another study recommended only surveillance for all 
asymptomatic patients with sRAML regardless of size as 
the natural history of these lesions has not been well char-
acterized and the annual growth rate of lesions is extremely 
Table 1. Summary of selected series which included prophylactic management against the risk of bleeding.
Method Lesions
Follow-up 
 duration (months)
Complications Outcome References
NSS sRAMP/TSC-AML 15–96 0–21.4% Preservation or renal 
function, rare renal 
impairment, recur-
rence 0–3.4%
(4, 5, 29, 32–38)
RPN sRAMP/TSC-AML 8–40 15–26% including 
Clavien Grade I–II
eGFR preservation 
and no recurrence
(39–41)
Embolization sRAMP/TSC-AML 20–85 multiple retreatments 
reported between 12 
and 50%, complication 
rate varied between 0 
and 19.5%
85–91% success rate, 
a mean size reduc-
tion of 25–72%, no 
bleeding or need for 
surgical interven-
tion was required in 
0–17%, no significant 
change of serum 
creatinine
(4, 8, 22, 42–50)
Observation sRAMP/TSC-AML 40–60 No bleeding or size 
change, growth in 
8%, need for inter-
vention in 5.6–13% 
or surgery in 29%
(26, 29, 51–55)
Everolimus TSC-AML 9.5–29 2 patients discontinued 
treatment because of 
adverse events, adverse 
events mostly grades 
1–2
42–54% clinical 
response (size 
reduction >50%), no 
bleeding reported in 
patients or controls
(2, 57)
AML, angiomyolipoma; eGFR, estimated glomerular filtration rate; NSS, nephron sparing surgery; RPN, robotic partial nephrectomy; 
sRAML, sporadic renal AML; TSC, tuberous sclerosis complex.
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slow  (52). The analysis included patients with RAML 
(n = 447) who had three or more radiologic imaging. Regard-
less of size, RAML was stable with no appreciable growth 
at a median follow-up of 43 months. It is noteworthy, how-
ever, that the median size of the lesions was 1 cm and 90% 
of the patients had lesions ≤4 cm. In addition, of the 47 pa-
tients with lesions >4 cm, 38% (n = 18) had an intervention. 
From the larger cohort (n = 2741), seven patients with lesions 
>4 cm were excluded and had a nephrectomy or PN because 
of bleeding (n = 3), pain (n = 1), or electively (n = 3). Recal-
culating interventions for lesions >4 cm, 53.2% of patients 
required an intervention or surgery. From these data, one 
may conclude that more than 90% of patients with RAML 
≤4 cm did not need an intervention, whereas more than half  
of patients with lesions >4 cm had an intervention or surgery.
Pregnancy and risk of bleeding
RAML and pregnancy constitute a challenging situation. 
In the absence of a large series, the risk of bleeding remains 
not well defined. Case reports imply that an accelerated 
growth of RAML may occur during pregnancy and subse-
quent pregnancies may have a higher chance of hemorrhagic 
complications warranting prophylactic treatment (12, 13). 
Bleeding may prompt emergency treatment. Conservative 
management and elective caesarian section were reported 
when the patient was asymptomatic, hemodynamically sta-
ble, or could be stabilized by blood transfusions (58–61). 
Treating a bleeding lesion by nephrectomy or PN may com-
promise the continuation of pregnancy (62). Meanwhile, case 
reports of embolization and nephrectomy during pregnancy 
with uneventful outcome were reported (63, 64). A literature 
review found 21 cases of bleeding RAML managed during 
pregnancy in the past 35 years (62). The reported manage-
ment included conservative treatment in eight women, em-
bolization in five women, and nephrectomy in seven women. 
Related fetal death was reported in two cases. The hemor-
rhagic shock itself  may lead to fetal demise (65). Few cases 
were reported where embolization was used to treat the preg-
nant mother (63, 64, 66). The risk of fetal exposure to radi-
ation must be considered. Once the mother has reached full 
term, the preferred method of delivery is through caesarian 
section. Cases were reported of RAML rupture, retroperito-
neal hemorrhage, and acute abdomen during or immediately 
after vaginal delivery (67, 68). One case was reported with un-
eventful course after vaginal delivery in a patient treated con-
servatively for RAML rupture (69). Other challenging special 
conditions were reported and successfully managed (70–74).
mTOR inhibitors and bleeding
Several studies showed that mTOR inhibition results in a clin-
ically significant reduction of TSC-RAML with acceptable 
tolerability and safety (2, 3, 75, 76). In 2012, everolimus was 
approved for the treatment of TSC-RAML. Treatment with 
everolimus for 1 year resulted in a reduction of the size of 
renal lesions by at least 50% in 53.3% of patients (77). These 
findings were confirmed in a clinical trial involving patients 
with TSC-RAML of at least 3 cm diameter (2). The clini-
cal response rate was 42%. In an open label extension of the 
trial at a median follow-up of 29 months, the response rate 
increased to 54% (57). No patient developed bleeding from 
the kidney during the trial or its extension. A meta-analysis 
suggested that everolimus treatment prevented bleeding in 
those patients (78). As the risk of bleeding is associated with 
larger lesion, it could be inferred that treatment with everoli-
mus will decrease the risk of bleeding by size reduction. How-
ever, there was no reported direct evidence that everolimus 
did decrease the risk of bleeding in TSC patients compared 
to controls (2). Being an oral medication that is generally well 
tolerated, everolimus is an attractive alternative for prophy-
laxis against renal hemorrhage with the caveats of adverse 
events (AE) related to its immunosuppression and metabolic 
effects (60). mTOR therapeutic effect is reversed after ces-
sation of treatment (75). Recommendations regarding the 
long-term duration of treatment have not been established. 
Additional everolimus benefits that may tip the balance in its 
favor are its concomitant therapeutic effect on brain lesions 
and safety on renal function. Everolimus has not been ap-
proved for the treatment of sRAML regardless of its size or 
associated risks.
Renal Malignancy
The issue of renal malignancy arises when a fat-poor AML is 
encountered, AML harboring RCC components is suspected 
of, or an epithelioid variant of the AML is present.
Fat-poor AML
RAML has a characteristic radiologic appearance based 
on its fat content. A fat-poor renal mass is treated as RCC, 
usually by PN or total nephrectomy depending on surgical 
feasibility. The diagnosis of RAML in this situation is post 
surgery. In a large series of 730 patients, fat-poor AML 
constituted 4.8% of lesions <4 cm surgically excised with a 
preoperative diagnosis of renal cancer (79). In another large 
series of patients treated surgically, fat-poor AML was found 
in 33–65% of lesions, most commonly in small single lesions 
and least commonly in TSC-associated lesions (80). Con-
sequently, preoperative diagnosis may prevent unnecessary 
surgery for a low-risk RAML. An attempt at preoperative di-
agnosis utilized a modification of imaging techniques and pa-
tient characteristics (79). Fat-poor AML tends to occur with 
smaller lesions, female gender, and younger age (79). Imaging 
modifications and novel image analysis try to demonstrate the 
presence of a minute amount of fat within the lesion. Such 
techniques include ultrasound (81), computed tomography 
(82, 83), and magnetic resonance imaging (MRI) (84–88). 
Preoperative diagnosis is possible by transcutaneous biopsy. 
Risks of renal angiomyolipoma
Journal of Kidney Cancer and VHL 2017; 4(4): 13–25 17
The presence of fat, HMB-45 markers, or smooth muscle 
histologic markers discloses the diagnosis. The indications 
of special imaging or biopsy to rule out fat-poor RAML 
have not been well defined. When does the managing phy-
sician suspect AML rather an RCC for a solid renal lesion? 
We propose that such situations may include the association 
with TSC, the presence of multiple lesions, association with 
triphasic AML lesions, history of AML, and inconclusive ra-
diological diagnosis.
Renal cell carcinoma
The development of RCC within a RAML is rare but pos-
sible. Follow-up of mass growth, imaging characteristics, 
and biopsy may disclose the nature of the lesion and prompt 
proper management. Coexistent renal cancer and RAML was 
found in 34 cases (1%) in nephrectomy or PN specimens car-
ried out for renal masses pooled from multiple centers (89). 
The association was found in both sporadic and TSC AML 
and the most common pathologic type was clear cell RCC. In 
a cross-sectional study of asymptomatic patients with TSC, 
2.2% had RCC (90). Even in the pediatric age group, one pa-
tient out of 145 with TSC-RAML developed RCC (30). In 
another study, a total of 54 RCC lesions were reported in 18 
patients with TSC (91). Most of the lesions (94%) were as-
sociated with AML. RCC was commonly multiple synchro-
nous, metachronous, and/or bilateral. The histologic types 
were chromophobe RCC (59%), RCC with smooth muscle 
stroma (30%), and granular eosinophilic type. A distinctive 
feature of all RCC lesions is negative HMB-45 immunostain-
ing. RCC was more common in females (13:5), developed at 
an early age, and had an indolent course at a mean follow-up 
of 52 months. An unusually high prevalence of concurrent 
RCC and RAML was reported in none-TSC patients. In a 
retrospective study of nephrectomy specimens for sRAML, 
concurrent RCC was found in 47% of lesions mostly of clear 
cell type (56%) (92).
Epithelioid RAML
The diagnosis of epithelioid RAML is difficult because of 
the radiologic similarity to triphasic AML. Epithelioid AML 
(eAML) was reported in 7.7% of AML cases subjected to his-
topathologic diagnosis (93). eAML has an aggressive behavior, 
leading to metastasis, renal vein/inferior vena cava invasion, 
and in one study only 50% survival at 3 years (94). eAML has 
fewer or no fat content and is less frequently bilateral com-
pared to classic AML. A study of a large series of patients with 
pure eAML reflected the aggressive behavior of the tumor in 
41 patients (95). At the time of presentation, 79% patients were 
symptomatic and 12 (29.3%) patients had already metastasis. 
A follow-up of 33 patients (median 24.5 months) revealed re-
currence in 17%, metastasis in 49%, and death in 33%. Another 
large series included 34 patients with eAML and atypia (96). 
Recurrence or metastasis was reported in 9 (26%) patients, 
four of whom died from the disease by 34 months. The rather 
aggressive behavior reported in these series might be related 
to histological characteristics of the lesions. The malignant 
behavior of eAML might be predicted by the proportion of 
epithelioid cells, tumor necrosis, the degree of nuclear atypia, 
and mitosis (93). Other studies showed a lower rate of aggres-
sive behavior. In one study, only 5 (6.4%) patients with RAML 
had an epithelioid histopathology and only one developed 
metastasis (97). In another study, only one patient developed 
metastasis out of 11 patients with eAML (98). A lower rate of 
metastatic behavior was reported in a large series of 20 patients 
with renal eAML where only one (5%) developed metastasis 
(99). The malignant potential of eAML might be related to p53 
mutation (97, 100). Preoperative diagnosis of eAML might be 
confused with RCC, particularly in cases which present with 
venous extension or metastasis (101). Several studies tried in 
retrospect to provide radiologic characteristics that may pre-
dict the diagnosis of eAML and differentiate it from classic 
triphasic AML and RCC (98, 102–104). Fine-needle aspiration 
(FNA) diagnosis of AML is difficult when the epithelioid type 
predominates. A group of lesions that were subjected to FNA 
subsequently proved AML on histopathology (105). The diag-
nosis was possible in only half the lesions, while in nearly half  
of the lesions FNA was nondiagnostic or erroneous. It remains 
to be seen that prospectively any radiologic characteristics or 
techniques can provide an accurate preoperative diagnosis of 
eAML.
For such a dismal tumor, it is noteworthy to mention that 
case reports of everolimus treatment of eAML showed a dra-
matic response of the lesion and metastasis (106, 107). The 
role of such a treatment needs to be defined.
Renal Impairment
There is a plethora of evidence that associated renal impair-
ment with RAML, particularly with TSC. In a cohort study, 
16% of patients reached a chronic kidney disease (CKD) 
stage 3 or higher during a 12-year follow-up (108). A steeper 
yearly decline of glomerular filtration rate (GFR) was found 
in patients with TSC-RAML compared to the normal pop-
ulation (108). Age and RAML size correlated with CKD. 
The mortality rate was significantly higher in TSC patients 
(8.3%), mainly related to renal causes (2.6%), compared to 
the normal population (4.8%) (109). A meta-analysis con-
firmed that significantly more CKD is prevalent in TSC pa-
tients compared to age-matched population and there is a 
decrease in renal function as age increases (78). Moreover, 
renal causes accounted for 27.5% of the mortality reported 
in treated TSC patients (110). Several TSC patients have been 
treated in dialysis centers and some had high mortality (111, 
112). Pediatric TSC patients may still develop renal insuffi-
ciency, though rarely (30).
Many review articles tried to explain the underlying pathol-
ogy of renal impairment in patients with TSC (31, 113). En-
croachment on the normal renal parenchyma or compression 
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was provided as a possible mechanism. These conclusions 
were based on a few original articles (110–112).
In a review of causes of mortality in patients with TSC, 40 
deaths related to TSC in 355 cases were reported (110). Renal 
causes accounted for 11 (27.5%) of these deaths. Two patients 
died from hemorrhage, two from renal malignancy, and seven 
from renal failure. The authors state that renal failure may 
have occurred because of angiomyolipoma, renal cysts, or 
both. Indeed, in an earlier report from the same group, 80% 
of the 15 patients who died had cystic lesions alone or with 
angiomyolipoma and three patients died from polycystic kid-
ney disease (PCK) (114). In another study, of 65 TSC patients 
treated in dialysis centers in France, AML alone accounted 
for 23.1% of cases, renal cysts for 18.5% of cases, AML with 
renal cysts for 53.8% of cases, and glomerulosclerosis and 
nephrocalcinosis for 4.6% of cases (111). Nephrectomy was 
carried out before dialysis in 21 (32.3%) patients and after di-
alysis in six patients. The indications of nephrectomy were se-
vere hemorrhage in six patients, renal cancer in eight patients, 
and AML in 13 patients. Eight patients died: six related to di-
alysis, one related to untreated uremia, and one due to septic 
shock. The underlying pathology of end-stage renal failure 
in 10 patients with TSC treated in Europe was AML alone 
in one patient, four had PCK, one had AML with cysts, two 
had atrophic kidneys with cysts, one patient had adenocarci-
noma, and in one patient pathology was unidentified (112).
Other studies have provided insights into the causes of 
renal impairment. In a cohort study documenting deteriora-
tion of renal function in TSC patients with RAML, there was 
a significant difference in CKD between patients who had em-
bolization and those who did not have (108). A confounding 
factor of the association of larger RAML with CKD is that 
larger lesions are subjected to more interventions including 
higher embolization rate and nephrectomy (109). Another 
confounding factor is the association with renal cysts either 
as a part of RAML pathology or associated with adult PCK 
mutation. In an epidemiologic study of patients with TSC, 
patients who consented to have an ultrasound evaluation, 
69% had RAML and 30% had renal cysts (115). In a cross-
sectional study of asymptomatic patients with TSC, 61% of 
patients had a renal lesion, 49% had AML, 32% had renal 
cysts, and 2.2% had renal carcinoma (90). The patients with 
any renal lesions had cysts alone or associated with AML in 
52.9%. Out of 45 patients who had a test for serum urea and 
creatinine, only four had elevated levels—three of them had 
cysts with or without AML lesions and one had only AML. 
The authors suggested that the presence of renal cysts con-
tributed to the renal dysfunction, which was also endorsed 
by previous reports (116, 117). A possible mechanism is the 
concomitant deletions affecting the TSC2 and PKD1 genes 
on chromosome 16p (118).
Some reports indicated that intervention was not  associated 
with renal impairment, while others showed that inter-
vention/surgery rather than the AML lesions was associated 
with deterioration of renal function (119, 120). The discrep-
ancy may be related to the relative proportions of sporadic 
versus TSC-RAML, where most of the reports associating 
renal impairment with RAML involve TSC patients.
Analysis of data from the above articles may lead to the 
conclusion that indeed renal impairment is associated with 
RAML, particularly in the TSC patients. The underlying 
mechanisms, however, might be disputed. Renal cysts alone 
or with AML were the most common cause that contributed 
to renal failure, followed by nephrectomy and intervention. A 
smaller number of patients may have had renal impairment 
because of RAML alone; however, no evidence explaining the 
underlying pathogenesis was provided. The significance of this 
observation is that treatments that target reduction of renal 
failure in patients with RAML should primarily aim at the re-
duction of nephrectomy and intervention complications. Sev-
eral novel approaches including mTOR inhibition may achieve 
this goal. Some patients will benefit from mTOR inhibition by 
reducing the size of RAML. It remains to be seen if any treat-
ment may modify the progression of renal cysts which may 
have a greater impact on the development of renal failure.
Risks Related to Management
RAML may prompt intervention or surgery as a preventive 
or therapeutic measure. A prospective cohort study reported 
an intervention in 48.3% of patients with sRAML (29). The 
primary surgical intervention was indicated mainly for pa-
tients with fat-poor RAML (76.3%) and for lesions >4 cm; 
PN constituted 65.8% of the procedures. Primary emboliza-
tion was scarcely used in the cohort (4.6%). Before January 
2000, incidentally presenting lesions constituted 27.6% of pa-
tients and surgical extirpation constituted 28.6% of interven-
tions; following that date, incidental presentation increased to 
72.4% and surgery to 48.6%. Another study of patients with 
RAML reported 50.8% active treatment in the form of sur-
gical intervention (79.8%) or embolization (20.2%) (120). At 
a mean follow-up of 64.8 months, 5.5% required additional 
intervention because of growth of lesions or hemorrhage. 
Others reported 48.3% interventions, 79.3% of which were 
PN or total nephrectomy (1). The indications for intervention 
were hemorrhage, pain, or suspicion of malignancy. Patients 
with TSC-RAML are particularly prone to such treatments. 
In a retrospective study of patients with TSC-RAML aged 
18 years or older, 25% received an intervention. The reported 
rates included 17.1–18.5% embolization, 5.1–7.7% PN, 4.3–
11.4% nephrectomy, 6.8–7.7% repeat embolization, and 1.7–
4.5% repeat PN (121). These figures were reported before the 
use of mTOR inhibitors to treat similar patients.
Nephrectomy and PN
In the early days, surgical excision in the form of nephrec-
tomy or PN of RAML was common for the management of 
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symptomatic cases (122), tumor hemorrhage, retroperitoneal 
hemorrhagic emergency (123), suspicion of malignancy (32), 
and later for prophylaxis. Surgical excision remains the only 
treatment that completely rids of the offending lesion, al-
though recurrence from other parts of the kidney may occur. 
Nephrectomy or PN leads to loss of renal tissue, but in an 
emergency, a nephrectomy could be lifesaving. Preoperative 
embolization of the offending lesion may permit resuscita-
tion and a well-planned PN and reduce the difficulty and 
complications of laparoscopic PN (124–126).
NSS was advocated for RAML at risk of  bleeding for pro-
phylaxis and for the suspicion of  malignancy. PN, whether 
open surgical, laparoscopic, or robotic assisted, became the 
common urologic procedure. The challenges of  surgery are 
related to high vascularity of  RAML, producing difficulty 
that may lead to total nephrectomy and renal impairment 
that may develop with longer warm ischemia time. Several 
early series were reported utilizing NSS for RAML (33, 36, 
127). Heidenreich et al. reported a summary of  10 series 
involving 101 patients prior to 2002 including their own 
(33). The indications for surgery were suspicion of  malig-
nancy, symptoms, or risk of  bleeding. Early postoperative 
complications included a urinary leak in a minority of  pa-
tients that required a secondary procedure. Renal function 
was maintained and no local recurrence was reported. An 
early series of  open PN (n = 58, median size 3.9 cm) was 
reported including seven patients with multiple ipsilateral 
lesions, two patients with bilateral lesions, and four patients 
with solitary kidneys (36). Intraoperative blood transfusion 
was needed in 23% of  cases. The early postoperative compli-
cation rate was 12.1%, most commonly due to ileus (8.6%) 
and urine leak (5.2%). At a median follow-up of  8 years, 
there were two AML recurrences (3.4%), no significant dif-
ference between preoperative and last serum creatinine was 
reported, and no de novo renal impairment was developed. 
A review of  more contemporary series of  NSS (2000–2010), 
open and laparoscopic, for RAML including 185 patients, 
reported higher complication rate (10.7–21.4% at mean 
follow-up of  26.4–96 months) and recurrence (3.4–5.9% at 
mean follow-up of  56.4–96 months) (4). Of  these patients, 
28 were also included in a previous review (33). Laparo-
scopic PN has similar surgical outcomes when performed 
for RAML in comparison to other renal tumors (38). At 
a median follow-up of  15 months, no AML recurrence 
or bleeding occurred. Lesion enucleation of  large RAML 
(n  =  31, range 9–15 cm) was carried out using an open 
technique (128). There was no significant change in periop-
erative creatinine. No complications or recurrences were 
reported. Retroperitoneal laparoscopy with enucleation of 
the lesions was described to minimize complications (129).
Robotic-assisted PN further facilitates the surgical proce-
dure. In a multicenter study of robotic PN for patients with 
large RAML (n = 40, median diameter 7.2 cm) and challeng-
ing anatomical characteristics (median nephrometry score 9), 
there were minimal perioperative complications and excellent 
renal function preservation (41). Preoperative embolization 
did not affect the outcome of the procedure. In another se-
ries reporting long-term follow-up of robotic PN for RAML 
(n = 23, median size 5.2 cm), at a median of 40 months fol-
low-up, 86.9% of GFR was preserved and no long-term 
complications requiring secondary intervention or AML re-
currence were reported (40). Robotic PN for smaller lesions 
(n = 53, median size 2.8 cm) included lesions suspicious for 
malignancy (79.2%), at risk of bleeding, or causing pain (39). 
Similarly, the procedure was associated with excellent preser-
vation or renal function (median 91% preservation of GFR), 
no surgical complications requiring secondary intervention 
or recurrence of lesions.
In summary, NSS is associated with no or minimal re-
currence of lesions, maintenance of renal function, and few 
manageable complications.
Embolization
A prophylactic embolization of lesions at high risk for bleed-
ing became more common. The procedure is minimally inva-
sive and has a high success rate (22, 42). Frequent retreatment, 
however, may be needed in nearly half of the patients and post-
embolization syndrome affecting as high as 86% (22). A recent 
review of contemporary series of embolization for RAML was 
reported (4). Seven articles from 2009 to 2014 including 196 
patients with a large mean lesion size ranging 7.8–15 cm re-
ported a complication rate of 0–19.5%. Repeat embolization 
was needed in 5.9–56.3% of cases and surgery in 0–14.8% at a 
mean follow-up of 14–85.2 months. In a meta-analysis of pa-
tients who received selective embolization for RAML followed 
for 39 months, self-limiting postembolization syndrome oc-
curred in 36%, another morbidity in 7%, and repeat emboliza-
tion or surgery was needed in 21% (130). The recurrence rate 
might be higher in TSC patients (131). Loss of renal function 
consequently may be encountered. Several reports of embol-
ization of RAML, however, reported no deterioration of renal 
function (23, 24, 132). Even with preexisting renal impairment, 
there was no significant change in renal function after embol-
ization alone or associated with NSS (132). In another study, 
in patients with TSC-RAML, there was no significant dete-
rioration of renal function attributed to prophylactic embol-
ization (49). The presence of contralateral normal functioning 
kidney may mask renal damage occurring on the embolized 
kidney. To answer this question, a prospective study evaluated 
split renal function before and after embolization using radio-
isotope renography and found no significant change of renal 
function on the treated kidney (133).
mTOR inhibitors
Everolimus was approved for the treatment of TSC-associ-
ated RAML. No serious AE was encountered that required 
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cessation of treatment in the clinical trials (2, 77). AE included 
stomatitis, acne-like skin lesions, amenorrhea, irregular men-
struation, and hypercholesterolemia. Open label extension 
of the clinical trial showed that everolimus is well tolerated 
and AE decreases over time (57). Other studies confirm the 
efficacy and safety of everolimus with manageable AE pro-
file (134, 135). Lower doses were also shown to be effective. 
The significant reduction of lesion size was maintained for 
36 months on a dose of 2.5–5 mg (136). A major concern 
for treating physicians is how long should the treatment con-
tinue as the effect of mTOR inhibition is reversible (75, 137). 
To continue the treatment for RAML, consideration should 
be given to long-term complications and the cost compared 
with other treatment modalities. The treating physician needs 
to observe metabolic complications that may cause dyslipi-
demia, hyperglycemia, immunosuppression-related compli-
cations, and fertility concerns and guide therapy accordingly 
(138). Several studies assessed the cost of health care for pa-
tients with TSC-RAML prior to approval of everolimus and 
found a high cost related to renal event management (108, 
139, 140). A retrospective analysis of commercially insured 
and Medicaid patients in the United States compared claims 
related to TSC-RAML to controls between 2000 and 2012 
(141). TSC was associated with higher incidence of hema-
turia, renal hemorrhage, CKD, renal failure, and hospital 
mortality than patients without TSC. The most significant 
differences were found in patients older than 18 years and 
for the incidence of hematuria and CKD. The health care 
annual cost was significantly higher for patients with TSC-
RAML versus controls (142). Currently, it is not clear how 
everolimus treatment may impact the cost of TSC-RAML in 
the long term.
Risk of Associated Conditions
TSC-RAML, unlike its sporadic counterpart, is associated 
with a myriad of conditions that pose a significant risk to pa-
tients (143). Seizures, hydrocephalus, and intellectual disabil-
ity are among the first presenting symptoms. The underlying 
neurological pathology includes cortical tubers, subependy-
mal nodules, and giant cell astrocytomas. Other serious 
conditions that are commonly found are lymphangioleiomy-
omatosis of the lungs, cardiac rhabdomyoma, and hepatic 
AML. A cohort of adult women with TSC recruited by the 
NIH for the study of LAM had many patients with respira-
tory complications (75%), seizers (54%), renal intervention 
(43%), and mortality (12%) (144).
Conclusion
RAML encompasses a wide spectrum of small lesions that 
need not be followed to massive bilateral lesions that pose 
life-threatening risks to the patient. The disease itself  or its 
treatment may contribute to the development of complica-
tions. With the development of interventional treatments, 
minimally invasive surgery, and oral targeted therapy, there is 
hope that such complications can be reduced to a minimum 
and there will be better longevity and quality of life for pa-
tients even with the most significant disease burden.
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